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Abstract
Aims To investigate the effect of intravitreal
dexamethasone implant (IVD) on central
foveal thickness (CFT), choroidal thickness
(CT) and its correlation with visual acuity
in eyes with refractory diabetic macular
oedema (DMO).
Methods This was a retrospective
interventional case-series. Thirty-ﬁve eyes
of 35 patients were treated with a single
injection of IVD because of refractory
DMO with CFT over 300 μm, and persistent
intraretinal and subretinal ﬂuid despite of
multiple intravitreal bevacizumab injections.
Patients were followed-up for 6 months for
the evaluation of CFT and subfoveal CT
by spectral-domain optical coherence
tomography.
Results All eyes (mean age: 59.4± 12.35
years; 18 males, 17 females) had been
previously treated with multiple bevacizumab
injections and showed persistent DMO
(mean number of injections 4.08± 2.98)
The preoperative logMAR BCVA was
0.49± 0.24, which gradually improved to
0.46± 0.32 at 6 months (P= 0.652) and 26%
gained two or more lines of Snellen visual
acuity. At baseline, the mean CFT was
526.29± 123.48 μm, which signiﬁcantly
improved to 316.15± 100.09 μm at 3 months
(Po0.001). However, CFT deteriorated to
457.07± 136.53 μm at 6 months (P= 0.051).
Similarly, the mean preoperative subfoveal
CT was 288.91± 36.47 μm and it decreased
to 266.85± 30.93 μm at 3 months (Po0.01),
but increased to 278.63± 32.55 μm at 6 months
(P= 0.137). The reduction of CFT from
baseline showed signiﬁcant correlation with
that of subfoveal CT at 3 months (P= 0.041)
and at 6 months (P= 0.008).
Conclusions In DMO refractory to multiple
bevacizumab injections, IVD signiﬁcantly
reduced CFT and subfoveal CT, with BCVA
improvement in one-fourth of the patients.
The reduction of CFT showed signiﬁcant
correlation with reduction of subfoveal CT.
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Introduction
Diabetic macular oedema (DMO) is one of
the leading causes of visual impairment in
patients with diabetic retinopathy.1 There are
many factors involved in the pathophysiology
of DMO, including vascular endothelial growth
factor (VEGF), which is known to have an
important role in increasing vascular
permeability in diabetic retinopathy,2 and
inﬂammatory cytokines associated with the
development of DMO.3–5
Among several treatment options available
for DMO, use of anti-VEGF agents have led to
effective treatment of DMO, and anti-VEGF
therapy has become one of the most commonly
performed treatment modalities for DMO.6
Intravitreal dexamethasone implants (Ozurdex;
Allergan, Irvine, CA, USA) is a sustained-release
biodegradable implant, and it was shown to be
effective for the treatment of DMO.7,8 Recent
studies showed that certain eyes with DMO
were resistant to anti-VEGF therapy,9 and
intravitreal injection of dexamethasone (IVD)
implant has proven to be a novel treatment
modality for persistent DMO,10,11 DMO in
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difﬁcult to treat vitrectomized eyes,12 and particularly in
cases unresponsive to multiple injections
of anti-VEGF agents.9
With the advent of enhanced depth imaging optical
coherence tomography (EDI-OCT), changes in choroidal
thickness (CT) have been reported in chorioretinal diseases
such as DMO, age-related macular degeneration, and
uveitis.13–15 Recent studies have revealed mixed results
of either increased or decreased CT relating to disease
severity or response to treatments for DMO.14,16 Although
the clinical implication of changes in CT and its exact role in
the pathophysiology of DMO remains undetermined, it
would be clinically meaningful to study the changes of
the choroid and evaluate the potential role of subfoveal CT
as a biomarker for treatment response after IVD as many
previous studies have implicated choroidal changes and its
potential role in the pathophysiology of DMO.17–19 Thus,
we hypothesized that DMO resistant to repeated anti-
VEGF therapy would show a favorable response to IVD
and that the subfoveal CT in DMO would show
meaningful changes in response to IVD treatment.
In this study, we evaluated the changes of the CFT and
subfoveal CT after IVD in eyes with DMO refractory to
multiple anti-VEGF injections. Furthermore, we evaluated
potential associations of subfoveal CT with changes of
CFT and visual acuity.
Materials and methods
Study subjects
This retrospective study enrolled 35 eyes of 35 patients with
refractory DMO who were treated with the IVD implants
(0.7 mg Ozurdex) at the Vitreoretinal Service Clinic of Yonsei
University Medical Center between January 2013 and
December 2013. All the eyes had been previously treated
with serial intravitreal anti-VEGF injections, and showed
persistent DMO. The interval between the last injection of
bevacizumab and the intravitreal injection of dexamethasone
implant was 1 month. Inclusion criteria for this study were
the following: (i) central foveal thickness (CFT) of 4300 μm
with persistent increased intraretinal ﬂuid and no
morphological improvement of DMO onOCT despite at least
three consecutive monthly injections of 1.25mg bevacizumab
(IVB, Avastin; Genentech, South San Francisco, CA, USA), (ii)
absence of any mechanical tractions exerted on the fovea, (iii)
absence of other retinal or choroidal pathologies, such as age-
related macular degeneration, (iv) OCT images of sufﬁciently
good quality in which retinal and choroidal morphological
changes could be discerned, (v) absence of evidence of
macular ischemia as documented on pre-treatment
ﬂuorescein angiography with a confocal scanning laser
ophthalmoscope (HRA 2; Heidelberg Engineering,
Heidelberg, Germany), and (vi) patients whose OCT was
taken in the morning ofﬁce hours between 0900 hours to
1200 hours to minimize the potential effect of circadian
variations on the measurement of CT.
Exclusion criteria were, diagnosis of glaucoma or
the history of elevated intraocular pressure (IOP),
previous intraocular surgery such as cataract surgery or
vitrectomy, laser treatment, use of intraocular or periocular
corticosteroids in the study eye within the previous
6 months, vision reduction due to causes other than DMO,
visually signiﬁcant cataract or media opacity obscuring
the precise visualization of choroidal layers, eyes with
vitreous hemorrhage, tractional retinal detachment,
signiﬁcant vitreomacular traction or presence of epiretinal
membrane involving the macula, on OCT, evidence of
structural damage to the macula that might compromise
improvement of best corrected visual acuity (BCVA) after
improvement of DMO, uncontrolled systemic conditions
(diabetes mellitus, hypertension), and eyes with spherical
equivalent refractive error of more than − 6 diopters.
All patients underwent a complete ophthalmic
evaluation, including slit lamp biomicroscopic
examination, fundus examination, measurement of BCVA,
IOP, and EDI-OCT (Cirrus HD-OCT; Carl Zeiss Meditec,
Dublin, CA, USA) for measurement of CFT and subfoveal
CT at baseline, and at 1, 3, and 6 months post injection.
This study was approved by the institutional review board
of Yonsei University College of Medicine (IRB approval
number: 3-2014-0113) and was conducted in accordance
with the tenets of the Declaration of Helsinki.
OCT image assessment
EDI-OCT was performed, and CFT was deﬁned as the
distance from the retinal pigment epithelium (RPE) to the
internal limiting membrane. CFT was measured on a 1-mm
circle centered on the fovea, with mapping protocol using
the OCT software (Carl Zeiss Meditec). Using digital
calipers provided by the Cirrus EDI-OCT software,
subfoveal CT was measured as the distance from the outer
border of the hyper-reﬂective line corresponding to the
RPE, perpendicular to the chorioscleral interface. A
magniﬁcation of at least 100–200% was used to place the
measurement line precisely at the outermost RPE layer
and at the chorioscleral interface. Figure 1 shows a
representative example pre operatively, and at 1, 3, and
6 months post injection. The measurements were
independently performed twice, by two different blinded
examiners (MK and YJC), and the average value was used
for calculations. The observers were masked to the
measurements, and to prevent bias, a sheet of paper was
used to cover the OCT image from the RPE and above, so
that OCT readers were not allowed to observe the retina
from the RPE. The reliability and repeatability of the
measurements were also evaluated.
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Intervention
IVD injection After topical 0.5% proparacaine
hydrochloride and 5% povidone-iodine application, the
implant was inserted directly into the vitreous cavity
through the pars plana, 3.5 mm from the limbus, using
a customized, single-use, 22-gauge applicator with a self-
sealing scleral injection.
Statistical analysis
Statistical analyses were performed using SPSS software
(version 21.0; SPSS, Chicago, IL, USA). For descriptive
purposes, qualitative variables are given, using percentage,
and quantitative data were reported as mean± SD.
For evaluation of treatment efﬁcacy within each patient,
post-injection subfoveal CT, CFT, and logMAR BCVA at
each visit were compared with those of baseline by paired
Student’s t-test. The Pearson’s correlation coefﬁcient
was used to evaluate the correlation between CFT and
subfoveal CT. A P-value of o0.05 was considered
statistically signiﬁcant.
Results
Baseline characteristics
A total of 35 eyes of 35 patients, all with type 2 diabetes,
that satisﬁed the inclusion and exclusion criteria were
enrolled in the study (Table 1). None of the phakic eyes
had visually signiﬁcant cataract at the time, or showed
increases in lens opacity by two grades or more from
baseline at post injection 6 months. All the eyes had
been previously treated with multiple intravitreal anti-
VEGF injections (mean injections 4.08± 2.98) and showed
persistent DMO, as deﬁned previously.
Central foveal thickness
The mean CFT decreased from 526.29± 123.4 μm at
baseline to 335.48± 104.32 μm after 1 month (Po0.001),
Figure 1 EDI-OCT images of a patient with refractory DMO treated with IVD implant. CFT and subfoveal CT at (a) baseline,
(b) 1 month, (c) 3 months, and (d) 6 months after IVD treatment. CFT was measured on the 1 mm Early Treatment Diabetic Retinopathy
Study (ETDRS) circle centered on the fovea, with the mapping protocol of the OCT software. Subfoveal CT (double-headed arrow) was
measured from the hyper-reﬂective line of the Bruch’s membrane to the chorioscleral interface (arrowheads).
Table 1 Baseline characteristics of patients with refractory
diabetic macular oedema
Clinical parameters
Eyes/patients 35/35
Age (years) 59.4± 12.35
Male/female 18/17
NPDR/PDR 20/15
Mean number of previous anti-VEGF injection 4.08± 2.98
HbA1c (%) 7.38± 1.45
Serum creatinine 0.81± 0.28
Axial length (mm) 23.43± 0.67
Phakic/pseudophakic eyes 8/27
Best corrected visual acuity (logMAR) 0.49± 0.24
Central foveal thickness (μm) 526.29± 123.4
Subfoveal choroidal thickness (μm) 288.91± 36.47
Abbreviations: NPDR, non PDR; PDR, proliferative diabetic retinopathy;
VEGF, vascular endothelial growth factor.
Values are presented as mean± SD.
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and to 316.15± 100.09 μm after 3 months (Po0.001).
All of the 35 eyes experienced a signiﬁcant decrease
in CFT and none of the eyes showed worsening or no
improvement at 1 and 3 months. However, the effect was
not sustained and there was an aggravation of DMO
with an increase of CFT to 457.07± 136.53 μm at 6 months,
and the changes of CFT eventually became statistically
insigniﬁcant at 6 months, compared with preoperative
CFT(P= 0.051; Figure 2a).
Subfoveal CT
The mean preoperative subfoveal CT was 288.91±36.47 μm
and was signiﬁcantly decreased to 260.19±33.20 μm at
1 month (Po0.001) and 266.85±30.93 μm at 3 months
(Po0.01). Similar to CFT, all the eyes experienced a decrease
in CT and none of the eyes showed increase or no change of
subfoveal CT at 1 and 3 months. However, at 6 months after
the treatment, subfoveal CT increased to 278.63±32.55 μm
(P=0.137; Figure 2b). The reduction (%) of subfoveal CT
from baseline showed signiﬁcant correlation with that of
CFT at 3 months (P=0.041) and at 6 months (P=0.008),
whereas the correlation was not statistically signiﬁcant at
1 month (P= 0.053; Figure 3).
Regarding the reliability and repeatability of the spectral-
domain OCT scan, within observers, mean subfoveal CT
difference was 0.312, and the standard deviation of the
difference was 3.14, whereas between different observers,
mean subfoveal CT difference was −0.57, and the standard
deviation of the difference was 4.83.
Best corrected visual acuity
The preoperative initial logMAR BCVA was 0.49± 0.24,
which gradually improved to 0.44± 0.24 at 1 month,
0.40± 0.24 at 3 months, and 0.46± 0.32 at 6 months
(Figure 2c). Although BCVA tended to improve gradually
until 3 months, and decreased after 6 months, the mean
changes in BCVA from baseline were not statistically
signiﬁcant (P= 0.086, P= 0.255, and P= 0.652, respectively).
However, 26% (9 eyes) gained 2 or more lines of Snellen
visual acuity at 6 months.
Figure 2 Chronological changes of (a) CFT, (b) mean subfoveal CT, and (c) mean BCVA in logarithm of the minimal angle of resolution
(logMAR), in refractory DMO eyes during 6 months follow-up. There was a signiﬁcant reduction of subfoveal CT at 1 and 3 months, but
not at 6 months. The mean CFT signiﬁcantly decreased at 1 month, and signiﬁcant improvement in CFT was maintained until 3 months,
but the mean CFT increased after 6 months of follow-up. Although BCVA tended to improve gradually until 3 months and decreased
after 6 months, the changes in BCVA from baseline were not statistically signiﬁcant. *Statistically signiﬁcant difference (Po0.05).
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Ocular/systemic complications
No patients developed any serious ocular and systemic
adverse events such as visually signiﬁcant cataracts,
endophthalmitis, retinal detachment, or RPE tears, except
for transient chemosis and subconjunctival hemorrhage.
Three eyes (8.6%) experienced transient elevation of IOP
to between 25 mmHg and 30 mmHg at post injection
1 month, which was controlled with dorzolamide
2%/timolol 0.5% (Cosopt; Merck & Co., Whitehouse
Station, NJ, USA).
Discussion
To the best of our knowledge, this is the ﬁrst study to
demonstrate changes in CT, after undergoing IVD, in
eyes with DMO refractory to multiple injections with
anti-VEGF agents. Our results showed that in recalcitrant
DMO, IVD resulted in signiﬁcant reduction of subfoveal
CT and CFT, at 1 and 3 months, during the 6-month
follow-up, and 26% of the eyes achieved 2 or more
lines of improvement in Snellen visual acuity at 6 months.
Furthermore, subfoveal CT decreased signiﬁcantly in
association with improvement of CFT after IVD injection.
Clinically, subfoveal CT changes in patients with
diabetic retinopathy have been reported by several
investigators, with mixed results of either increased
or decreased CT in association with disease severity
or different treatments of eyes with DMO. Increase
of CT was noted as the severity of diabetic retinopathy
worsened from mild-to-moderate, from the non-
proliferative stage to proliferative stage,20 and in eyes
with DMO compared with those without DMO,14 whereas
signiﬁcant reduction of CT was found in other studies.21,22
Regarding the effect of speciﬁc treatment on subfoveal
CT, a recent study showed that intravitreal triamcinolone
injection caused signiﬁcant reduction of subfoveal CT,
whereas such reduction was not observed in those
receiving intravitreal anti-VEGF injections.16 However,
another recent study by Yiu et al23 showed signiﬁcant
decrease of subfoveal CT after multiple anti-VEGF
injections. In their study, however, the decrease of
subfoveal CT after anti-VEGF injection was not associated
with either the number of injections, changes in BCVA,
or CFT. In our study, IVD resulted in signiﬁcant reduction
of subfoveal CT in association with improvement of CFT
at post injection 1 and 3 months, but the effect seemed
to decrease at 6 months and the change of subfoveal CT
was not signiﬁcantly associated with changes in BCVA.
Chronic inﬂammation has been considered central in
the pathogenesis of DMO. In addition to VEGF, many
inﬂammatory cytokines have been reported to have
crucial roles in the development of DMO.3–5 Histological
studies of retina and choroid in patients with diabetic
retinopathy have shown various changes of choroidal
vasculature, such as accumulation of inﬂammatory cells,
focal dilation or narrowing, and the development of
sinus-like structures between the choroidal lobules.24–26
Furthermore, various cytokines and growth factors that
promote DMO may also inﬂuence choroidal vasculature,
which may account for changes in CT, as many previous
studies have implicated choroidal changes in the
pathophysiology of DMO.17–19
IVD delivers sustained release of corticosteroid and has
proven to be an effective treatment modality for DMO.9–12
Corticosteroids block production of inﬂammatory
cytokines and VEGF,27 inhibit leukostasis,28 improve
the barrier function of vascular endothelial cell tight
junctions,29 inhibit endothelial nitric oxide synthase,30
reduce tissue oedema, and decrease the release of
prostaglandins and histamines,31 all of which could
cause vasodilation and choroidal thickening, potentially
affecting ocular perfusion pressure.32 IVD, therefore,
could exert its therapeutic effect not only on the retina,
but also on the choroid, by decreasing the production
of inﬂammatory cytokines and factors that could increase
CT. In particular, inﬂammatory cytokines may have more
important roles than VEGF in eyes with DMO resistant
to serial anti-VEGF injections; past studies have shown
that although VEGF is correlated with the severity of
diabetic retinopathy, no signiﬁcant correlation was shown
between VEGF level and DMO, whereas inﬂammatory
factors such as IL-6 and MCP-1 have shown signiﬁcant
correlation with DMO.33–37 This may explain the
favorable morphological improvement in our study
of CT and CFT to IVD, in eyes with refractory DMO.
Although there was a trend toward improvement in
BCVA after IVD and BCVA improved by 2 or more
lines in 26% of all the eyes treated with IVD, it did not
lead to a statistically signiﬁcant improvement in all the
Figure 3 The reduction (%) of CFT from baseline showed
signiﬁcant correlation with that of subfoveal CT at 3 months
(P= 0.041) and at 6 months (P= 0.008), whereas the correlation
was not statistically signiﬁcant at 1 month (P= 0.053).
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eyes. A recent study by Lazic et al9 showed that patients
switching to IVD, after an initial three consecutive
anti-VEGF injections, showed signiﬁcant improvement
in BCVA. In our study, however, despite the signiﬁcant
morphological improvement of DMO, only 26% of the eyes
achieved two or more lines of improvement at 6 months
and we speculate that this may be attributable to cumulative
damage sustained over a long period of time before
switching to IVD. Other recent studies reported similar
results showing that despite reduction
of the DMO after intravitreal triamcinolone, signiﬁcant
improvement of vision was not achieved.16 Because of
the chronic nature of DMO in our study, eyes may have
already sustained chronic and irreversible microstructural
damage to photoreceptors, and this may have caused
a limitation on the improvement of visual acuity.
Perhaps, it may be more effective to perform IVD injection
at an early stage before imposing burdens of multiple anti-
VEGF injections on patients and it may lead to concurrent
improvement of visual acuity along with morphological
improvement of DMO before eyes sustain chronic damage
to the photoreceptors in the macula. Also, the effect of IVD
may not last for 6 months and additional IVD injection at
sometime between 3 and 6 months might help sustain the
anatomical beneﬁt attained from initial injection of IVD in
terms of reduction of CFT and CT. Future studies evaluating
which types of DMO are driven more by proinﬂammatory
cytokines other than VEGF and thus respond more
favorably to IVD would be helpful in determining IVD as
the primary treatment of choice for DMO.
Our study had several limitations, including the
retrospective nature of the work, relatively small number
of patients, and short duration of 6 months follow-up.
Previous treatment with multiple injections of anti-VEGF
agents, before IVD, might have exerted potential
inﬂuence on the measurement of CT, but the potential
effect of anti-VEGF on subfoveal CT may be minimal
in eyes with DMO, as shown in previous studies.16 Also,
as IVD’s therapeutic effect may not last for the expected
6 months, patients may beneﬁt from additional IVD
injection at sometime around 4–5 months, but this was
not investigated in our study. The deﬁnition of refractory
DMO may vary among different studies and it is not
a universal term. Therefore, the results of our study
may not necessarily apply to other studies with different
protocols and different deﬁnitions of refractory DMO.
The heterogeneity of the study population with regards
to multiple factors may affect subfoveal CT including
age, axial length and refractive error, but in our study,
subfoveal CT was compared within the same eye
before and after the treatment, thereby excluding any
confounding effect that may arise in comparing subfoveal
CT between two different population group. The use of
manual segmentation in the measurement of CT was also
a limitation. Also, the CT was measured at the subfoveal
area only and the interpretation of this ﬁnding cannot be
extrapolated to the whole choroid.
Serial anti-VEGF injections for treatment of DMO
presents a great burden on patients and physicians,
particularly in cases resistant to anti-VEGF injections,
leading to poor patient compliance and frustrations.
Intravitreal triamcinolone may be a viable option for
refractory DMO,38 but it is known to be associated with
complications such as cataract and endophthalmitis.39,40
IVD delivers sustained release of corticosteroid without
causing serious adverse effects, and seems to be an effective
treatment modality for DMO, particularly in anti-VEGF
resistant cases. It appears to exert its therapeutic effect
on the retina in association with reduction of CT, but the
exact mechanism remains to be determined.
In conclusion, in patients with DMO non-responsive to
multiple anti-VEGF injections, IVD signiﬁcantly reduced
subfoveal CT and CFT during 6 months follow-up, and
it led to signiﬁcant BCVA improvement in one-fourth
of the patients. The reduction of CFT showed signiﬁcant
correlation with reduction of subfoveal CT. To investigate
this relationship further, in the future, a large prospective
randomized controlled trial is warranted.
Summary
What was known before
K Certain eyes with DME are resistant to anti-VEGF
therapy–CT was related to disease severity or response to
treatments for DME.
K Subfoveal CT was thicker in eyes with DME than in those
without DME.
What this study adds
K In DME refractory to multiple injections with anti-VEGF
agents, IVD implant signiﬁcantly reduced subfoveal CT
and CFT during the 6-month follow-up with BCVA
improvement in one-fourth of the patients.
K Subfoveal CT decreased signiﬁcantly in association with
improvement of CFT after IVD injection.
Conﬂict of interest
The authors declare no conﬂict of interest.
Acknowledgements
This study was supported by a Faculty Research Grant
of Yonsei University College of Medicine for 2012 (3-2012-
0137).
References
1 Antonetti DA, Klein R, Gardner TW. Diabetic retinopathy.
N Engl J Med 2012; 366(13): 1227–1239.
Effect of Ozurdex in persistent diabetic macular oedema
M Kim et al
723
Eye
2 Adamis AP, Miller JW, Bernal MT, D'Amico DJ, Folkman J,
Yeo TK et al. Increased vascular endothelial growth factor
levels in the vitreous of eyes with proliferative diabetic
retinopathy. Am J Ophthalmol 1994; 118(4): 445–450.
3 Arimura N, Otsuka H, Yamakiri K, Sonoda Y, Nakao S,
Noda Y et al. Vitreous mediators after intravitreal
bevacizumab or triamcinolone acetonide in eyes with
proliferative diabetic retinopathy. Ophthalmology 2009; 116
(5): 921–926.
4 Funatsu H, Noma H, Mimura T, Eguchi S. Vitreous
inﬂammatory factors and macular oedema. Br J Ophthalmol
2012; 96(2): 302–304.
5 Funatsu H, Noma H, Mimura T, Eguchi S, Hori S.
Association of vitreous inﬂammatory factors with diabetic
macular edema. Ophthalmology 2009; 116(1): 73–79.
6 Brown DM, Nguyen QD, Marcus DM, Boyer DS, Patel S,
Feiner L et al. Long-term outcomes of ranibizumab therapy
for diabetic macular edema: the 36-month results from two
phase III trials: RISE and RIDE. Ophthalmology 2013; 120(10):
2013–2022.
7 Boyer DS, Yoon YH, Belfort Jr R, Bandello F, Maturi RK,
Augustin AJ et al. Three-year, randomized, sham-controlled
trial of dexamethasone intravitreal implant in patients with
diabetic macular edema. Ophthalmology 2014; 121(10):
1904–1914.
8 Gillies MC, Lim LL, Campain A, Quin GJ, Salem W, Li J et al.
A randomized clinical trial of intravitreal bevacizumab
versus intravitreal dexamethasone for diabetic macular
edema: the BEVORDEX study. Ophthalmology 2014; 121(12):
2473–2481.
9 Lazic R, Lukic M, Boras I, Draca N, Vlasic M, Gabric N et al.
Treatment of anti-vascular endothelial growth factor-
resistant diabetic macular edema with dexamethasone
intravitreal implant. Retina 2014; 34(4): 719–724.
10 Haller JA, Kuppermann BD, Blumenkranz MS, Williams GA,
Weinberg DV, Chou C et al. Randomized controlled trial of
an intravitreous dexamethasone drug delivery system in
patients with diabetic macular edema. Arch Ophthalmol 2010;
128(3): 289–296.
11 Pacella E, Vestri AR, Muscella R, Carbotti MR, Castellucci M,
Coi L et al. Preliminary results of an intravitreal
dexamethasone implant (Ozurdex(R)) in patients with
persistent diabetic macular edema. Clin Ophthalmol 2013; 7:
1423–1428.
12 Boyer DS, Faber D, Gupta S, Patel SS, Tabandeh H, Li XY et al.
Dexamethasone intravitreal implant for treatment of diabetic
macular edema in vitrectomized patients. Retina 2011; 31(5):
915–923.
13 Jonas JB, Forster TM, Steinmetz P, Schlichtenbrede FC,
Harder BC. Choroidal thickness in age-related macular
degeneration. Retina 2014; 34(6): 1149–1155.
14 Kim JT, Lee DH, Joe SG, Kim JG, Yoon YH. Changes in
choroidal thickness in relation to the severity of retinopathy
and macular edema in type 2 diabetic patients. Invest
Ophthalmol Vis Sci 2013; 54(5): 3378–3384.
15 Kim M, Kim H, Kwon HJ, Kim SS, Koh HJ, Lee SC.
Choroidal thickness in Behcet's uveitis: an enhanced depth
imaging-optical coherence tomography and its association
with angiographic changes. Invest Ophthalmol Vis Sci 2013; 54
(9): 6033–6039.
16 Sonoda S, Sakamoto T, Yamashita T, Otsuka H, Shirasawa M,
Kakiuchi N et al. Effect of intravitreal triamcinolone acetonide
or bevacizumab on choroidal thickness in eyes with diabetic
macular edema. Invest Ophthalmol Vis Sci 2014; 55(6):
3979–3985.
17 Cao J, McLeod S, Merges CA, Lutty GA. Choriocapillaris
degeneration and related pathologic changes in human
diabetic eyes. Arch Ophthalmol 1998; 116(5): 589–597.
18 Freyler H, Prskavec F, Stelzer N. Diabetic choroidopathy—
a retrospective ﬂuorescein angiography study.
Preliminary report. Klin Monbl Augenheilkd 1986; 189(2):
144–147.
19 Hua R, Liu L, Wang X, Chen L. Imaging evidence of diabetic
choroidopathy in vivo: angiographic pathoanatomy and
choroidal-enhanced depth imaging. PLoS One 2013; 8(12):
e83494.
20 Regatieri CV, Branchini L, Carmody J, Fujimoto JG, Duker JS.
Choroidal thickness in patients with diabetic retinopathy
analyzed by spectral-domain optical coherence tomography.
Retina 2012; 32(3): 563–568.
21 Unsal E, Eltutar K, Zirtiloglu S, Dincer N, Ozdogan Erkul S,
Gungel H. Choroidal thickness in patients with diabetic
retinopathy. Clin Ophthalmol 2014; 8: 637–642.
22 Gerendas BS, Waldstein SM, Simader C, Deak G, Hajnajeeb B,
Zhang L et al. Three-dimensional automated choroidal
volume assessment on standard spectral-domain optical
coherence tomography and correlation with the level of
diabetic macular edema. Am J Ophthalmol 2014; 158(5):
1039–1048.
23 Yiu G, Manjunath V, Chiu SJ, Farsiu S, Mahmoud TH.
Effect of anti-vascular endothelial growth factor therapy
on choroidal thickness in diabetic macular edema. Am J
Ophthalmol 2014; 158(4): 745–751 e742.
24 McLeod DS, Lefer DJ, Merges C, Lutty GA. Enhanced
expression of intracellular adhesion molecule-1 and
P-selectin in the diabetic human retina and choroid. Am J
Pathol 1995; 147(3): 642–653.
25 Hidayat AA, Fine BS. Diabetic choroidopathy. Light and
electron microscopic observations of seven cases.
Ophthalmology 1985; 92(4): 512–522.
26 Fryczkowski AW, Sato SE, Hodes BL. Changes in the
diabetic choroidal vasculature: scanning electron microscopy
ﬁndings. Ann Ophthalmol 1988; 20(8): 299–305.
27 Wang K, Wang Y, Gao L, Li X, Li M, Guo J. Dexamethasone
inhibits leukocyte accumulation and vascular permeability
in retina of streptozotocin-induced diabetic rats via reducing
vascular endothelial growth factor and intercellular
adhesion molecule-1 expression. Biol Pharm Bull 2008; 31(8):
1541–1546.
28 Tamura H, Miyamoto K, Kiryu J, Miyahara S, Katsuta H,
Hirose F et al. Intravitreal injection of corticosteroid
attenuates leukostasis and vascular leakage in experimental
diabetic retina. Invest Ophthalmol Vis Sci 2005; 46(4):
1440–1444.
29 Antonetti DA, Wolpert EB, DeMaio L, Harhaj NS, Scaduto Jr
RC . Hydrocortisone decreases retinal endothelial cell water
and solute ﬂux coincident with increased content and
decreased phosphorylation of occludin. J Neurochem 2002; 80
(4): 667–677.
30 Liu Y, Mladinov D, Pietrusz JL, Usa K, Liang M.
Glucocorticoid response elements and 11 beta-
hydroxysteroid dehydrogenases in the regulation of
endothelial nitric oxide synthase expression. Cardiovasc Res
2009; 81(1): 140–147.
31 Yamamoto Y, Gaynor RB. Therapeutic potential of inhibition
of the NF-kappaB pathway in the treatment of inﬂammation
and cancer. J Clin Invest 2001; 107(2): 135–142.
Effect of Ozurdex in persistent diabetic macular oedema
M Kim et al
724
Eye
32 Kim M, Kim SS, Kwon HJ, Koh HJ, Lee SC. Association
between choroidal thickness and ocular perfusion pressure
in young, healthy subjects: enhanced depth imaging optical
coherence tomography study. Invest Ophthalmol Vis Sci 2012;
53(12): 7710–7717.
33 Dong N, Xu B, Wang B, Chu L. Study of 27 aqueous humor
cytokines in patients with type 2 diabetes with or without
retinopathy. Mol Vis 2013; 19: 1734–1746.
34 Yoshimura T, Sonoda KH, Sugahara M, Mochizuki Y,
Enaida H, Oshima Y et al. Comprehensive analysis of
inﬂammatory immune mediators in vitreoretinal diseases.
PLoS One 2009; 4(12): e8158.
35 Funatsu H, Yamashita H, Noma H, Mimura T, Nakamura S,
Sakata K et al. Aqueous humor levels of cytokines are related to
vitreous levels and progression of diabetic retinopathy in diabetic
patients. Graefes Arch Clin Exp Ophthalmol 2005; 243(1): 3–8.
36 Oh IK, Kim SW, Oh J, Lee TS, Huh K. Inﬂammatory and
angiogenic factors in the aqueous humor and the
relationship to diabetic retinopathy. Curr Eye Res 2010; 35
(12): 1116–1127.
37 Sonoda S, Sakamoto T, Yamashita T, Shirasawa M, Otsuka H,
Sonoda Y. Retinal morphologic changes and concentrations of
cytokines in eyes with diabetic macular edema. Retina 2014; 34
(4): 741–748.
38 Martidis A, Duker JS, Greenberg PB, Rogers AH, Puliaﬁto CA,
Reichel E et al. Intravitreal triamcinolone for refractory
diabetic macular edema. Ophthalmology 2002; 109(5):
920–927.
39 Moshfeghi DM, Kaiser PK, Scott IU, Sears JE, Benz M,
Sinesterra JP et al. Acute endophthalmitis following
intravitreal triamcinolone acetonide injection. Am J
Ophthalmol 2003; 136(5): 791–796.
40 Jaissle GB, Szurman P, Bartz-Schmidt KU. Ocular side effects
and complications of intravitreal triamcinolone acetonide
injection. Ophthalmologe 2004; 101(2): 121–128.
Effect of Ozurdex in persistent diabetic macular oedema
M Kim et al
725
Eye
